Neuropsychological consequences of HIV and substance abuse: A literature review and implications for treatment and future research

Current Drug Abuse Reviews

Volumn 2, Issue 2, 2009, Pages 143-156

  Norman, Lisa R ^a   Basso, Michael ^b   Kumar, Anil ^c   Malow, Robert ^d  

^a PONCE SCHOOL OF MEDICINE   (Puerto Rico)

^b UNIVERSITY OF TULSA   (United States)

^c UNIVERSITY OF MISSOURI ST LOUIS   (United States)

^d FLORIDA INTERNATIONAL UNIVERSITY   (United States)

Author keywords

Future research; HIV; Neuropsychology; Substance abuse; Treatment

Indexed keywords

ALCOHOL; AMPHETAMINE; ANTIRETROVIRUS AGENT; CANNABIS; COCAINE; OPIATE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ALCOHOLISM; BEHAVIOR DISORDER; BRAIN ATROPHY; BRAIN DYSFUNCTION; CANNABIS ADDICTION; CLINICAL FEATURE; COCAINE DEPENDENCE; COGNITIVE THERAPY; COMORBIDITY; DEMENTIA; DISEASE COURSE; DISEASE EXACERBATION; GROUP THERAPY; HEALTH BEHAVIOR; HEALTH PROGRAM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICAL LITERATURE; MEDICAL RESEARCH; MILD COGNITIVE IMPAIRMENT; MORBIDITY; MORTALITY; NEUROLOGIC EXAMINATION; NEUROPSYCHOLOGY; OPIATE ADDICTION; PATHOPHYSIOLOGY; PATIENT CARE; PATIENT COUNSELING; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; REVIEW; RISK FACTOR; SUBSTANCE ABUSE; TREATMENT OUTCOME; VIRUS TRANSMISSION; ADDICTION; COGNITIVE DEFECT; HUMAN IMMUNODEFICIENCY VIRUS 1; MENTAL DISEASE; PATIENT COMPLIANCE; PSYCHOLOGICAL ASPECT;

ANTI-HIV AGENTS; BIOMEDICAL RESEARCH; COGNITION DISORDERS; HIV INFECTIONS; HIV-1; HUMANS; MENTAL DISORDERS; PATIENT COMPLIANCE; SUBSTANCE-RELATED DISORDERS;

EID: 70349901340     PISSN: 18744737     EISSN: None     Source Type: Journal    
DOI: 10.2174/1874473710902020143     Document Type: Review

References (186)

1. UNAIDS, 2006. AIDS Epidemic Update - December 2006. Joint United Nations Programme on HIV/AIDS, Geneva, Switzerland.
2. Hinkin CH, Barclay TR, Castellon SA, et al. Drug use and medication adherence among HIV-1 infected individuals. AIDS Behav 2007; 11(2): 185-94.
3. Martin EM, Nixon H, Pitrak DL, et al. Characteristics of prospective memory deficits in HIV-seropositive substance-dependent individuals: preliminary observations. J Clin Exp Nueropsychol 2007; 29(5): 496-504.
4. Kopnisky KL, Bao J, Lin YW. Neurobiology of HIV, psychiatric and substance abuse comorbidity research: Workshop report. Brain Behav Immun 2007; 21: 428-41.
5. Gonzalez-Scarano F, Martin-Garcia J. The neuropathogenesis of AIDS. Nat Rev Immunol 2005; 5: 69-81.
6. Navia BA, Cho ES, Petito CK, et al. The AIDS dementia complex: II. Neuropathology. Ann Neurol 1986; 19: 525-35.
7. Mattson MP, Haughey NJ, Nath A. Cell death in HIV dementia. Cell Death Differ 2005; 12: 893-904.
8. McArthur JC, Selnes OA, Glass JD, et al. HIV dementia. Incidence and risk factors. Research Publications - Association for Research in Nervous and Mental Disorders 1994; 2: 251-72.
9. Rausch DM, Stover ES. Neuroscience research and AIDS. Prog Neuropsychopharmacol Biol Psychiatry 2001; 25: 231-57.
10. Jernigan TL, Gamst AC, Archibald SL, et al. Effects of methamphetamine dependence and HIV infection on cerebral morphology. Am J Psychiatry 2005; 162: 1461-72.
11. Kim DM, Tien R, Byrum C, et al. Imaging in acquired immune deficiency syndrome dementia complex (AIDS dementia complex): a review. Prog Neuropsychopharmacol Biol Psychiatry 1996; 20: 349-70.
12. Paul R, Cohen R, Navia B. Relationships between cognition and structural neuroimaging findings in adults with human immunodeficiency virus type-1. Neurosci Biobehav Rev 2002; 26: 353-9.
13. Wiley CA, Lopresti BJ, Becker JT, et al. Positron emission tomography imaging of peripheral benzodiazepine receptor binding in human immunodeficiency virus-infected subjects with and without cognitive impairment. J Neurovirol 2006; 12: 262-71.
14. Castello JM, Sherman SJ, Courtney MG, et al. Altered hippocampal-prefrontal activation in HIV patients during episodic memory encoding. Neurology 2006; 66: 1688-95.
15. Ernst T, Chang L, Jovicich J. Abnormal brain activation on functional MRI in cognitively asymptomatic HIV patients. Neurology 2002; 59: 1343-49.
16. Nielsen-Bohlman L, Fein G, Boyle D, et al. N400 event-related potential reduction indexes: early central nervous system impairment in HIV. J NeuroAIDS 2002; 2: 51-65.
17. Ances BM, Roc AC, Wang J, et al. Caudate blood flow and volume are reduced in HIV+ neurocognitively impaired patients. Neurology 2006; 66: 862-6.
18. Moore DJ, Masliah E, Rippeth JD, et al. Cortical and subcortical neurodegeneration is associated with HIV neurocognitive impairment. AIDS 2006; 20: 879-87.
19. Chang L, Ernst T, Witt MD, et al. Relationships among brain metabolites, cognitive function, and viral loads in antiretroviral-naïve HIV patients. Neuroimage 2002; 17: 1638-48.
20. Cloak CC, Chang L, Ernst T. Increased frontal white matter diffusion is associated with glial metabolites and psychomotor slowing in HIV. J Neuroimmunol 2004; 157: 147-52.
21. Patel SH, Kolson DL, Glosser G, et al. Correlation between percentage of brain parenchymal volume and neurocognitive performance in HIV-infected patients. AJNR Am J Neuroradiol 2002; 23: 543-9.
22. Wood S, Grant I. Neuropsychology of HIV. In: The neurology of AIDS, Gendelman HE, Grant I, Everall IP, Lipton SA, Swindells S, Eds. New York: Oxford University Press 2005; pp. 607-16.
23. Vanderploeg, RD. Clinician's guide to neuropsychological assessment, 2nd edition. Mahwah, NJ: Lawrence Erlbaum Associates 2000.
24. Grant I, Sector N, McArthur J. HIV neurocognitive disorders. In The Neurology of AIDS. Gendelman HE, Grant I, Everall P, Lipton SA Swindells S, Eds. New York: Oxford Press. 2005; pp. 357-73.
25. Tekin S, Cummings JL. Frontal-subcortical neuronal circuits and clinical neuropsychiatry: an update. J Psychosom Res 2002; 53: 647-54.
26. Heaton RK, Grant I, Butters N, et al. The HNRC 500-neuropsychology of HIV infection at different disease stages. HIV Neurobehavioral Research Center. J Int Neuropsychol Soc 1995; 1: 231-51.
27. Levin HS, Williams DH, Borucki, MJ, et al. Magnetic resonance imaging and neuropsychological findings in human immunodeficiency virus infection. J Acquir Immune Defic Disorders 1990; 3: 757-62.
28. Van Gorp WG, Satz P, Hinkin C, et al. Metacognition in HIV-1 seropositive asymptomatic individuals: self-ratings versus objective neuropsychological performance. Multicenter AIDS Cohort Study (MACS). J Clin Exp Neuropsychol 1991; 13: 812-9.
29. Collier AC, Marra C, Coombs RW, et al. Central nervous system manifestations in human immunodeficiency virus without AIDS. J Acquir Immune Defic Syndr 1992; 5(3): 229-41.
30. Bornstein RA, Nasrallah HA, Para MF, et al. Duration of illness and neuropsychological performance in asymptomatic HIV infection. J Neuropsychiatry Clin Neurosci 1994; 6: 160-4.
31. Martin EM, Robertson LC, Sorensen DJ, Jagust WJ, Mallon KF, Chirurgi VA. Speed of memory scanning is not affected in early HIV-1 infection. J Clin Exp Nueropsychol 1993; 15(2): 311-20.
32. Grant I, Atkinson JH, Hesselink JR, et al. Evidence for early central nervous system involvement in the acquired immunodeficiency syndrome (AIDS) and other human immunodeficiency virus (HIV) infections. Studies with neuropsychologic testing and magnetic resonance imaging. Ann Int Med 1987; 107: 828-36.
33. Reger M, Welsh R, Razani J, et al. A meta-analysis of the neuropsychological sequelae of HIV infection. J Inter Neuropsychol Soc 2002; 8: 410-24.
34. Cysique LA, Maruff P, Brew BJ. The neuropsychological profile of symptomatic AIDS and ADC patients in the pre-HAART era: a meta-analysis. J Intern Neuropsychol Soc 2006; 12: 368-82.
35. Rubinow DR, Joffe RT, Brouwers P, et al. Neuropsychiatric impairment in patients with AIDS. Adv Biochem Psychopharmacol 1988; 44: 111-5.
36. White DA, Heaton RK, Monsch AU, et al. Neuropsychological studies of asymptomatic human immunodeficiency virus-type-1 infected individuals. J Internat Neuropsycholog Soc 1995; 1: 304-15.
37. Baldewicz TT, Leserman J, Silva SG, et al. Changes in neuropsychological functioning with progression of HIV-1 infection: results of an 8-year longitudinal investigation. AIDS Behav 2004; 8(3): 345-55.
38. Villa G, Solida A, Moro E, et al. Cognitive impairment in asymptomatic stages of HIV infection. A longitudinal study. Eur Neurol 1996; 36(3): 125-33.
39. Antinori A, Arendt G, Becker JT, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology 2007; 69: 1789-99.
40. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders DSM-IV-TR Fourth Edition. Arlington, VA: American Psychiatric Association 1994.
41. Rubinow DR, Joffe RT, Brouwers P, et al. Neuropsychiatric impairment in patients with AIDS. Adv Biochem Psychopharmacol 1988; 44: 111-5.
42. Stern RA, Silva SG, Chaisson N, et al. Influences of cognitive reserve on neuropsychological functioning in asymptomatic human immunodeficiency virus infection. Arch Neurol 1996; 53(2): 148-53.
43. Robertson KR, Robertson WT, Ford SW, et al. Highly active antiretroviral therapy improves neurocognitive functioning. J Acquir Immune Defic Syndr 2004; 36: 562-6.
44. Tozzi V, Balestra P, Galgani S, et al. Positive and sustained effects of highly active antiretroviral therapy on HIV-1 associated neurocognitive impairment. AIDS 1999; 13: 1889-97.
45. Sector N. The epidemiology of human immunodeficiency virusassociated neurological disease in the era of highly active antiretroviral therapy. J Nuerovirol 2002; 8(Suppl 2): 115-21.
46. Tozzi V, Balestra P, Galgani S, et al. Changes in neurocognitive performance in a cohort of patients treated with HAART for 3 years. J Acquir Immune Defic Syndr 2001; 28(1): 19-27.
47. Bornstein RA, Nasrallah HA, Para MF, et al. Rate of CD4 decline and neuropsychological performance in HIV infection. Arch Neuro 1991; 48: 704-7.
48. Margolin A, Avants SK, Warburton LA, et al. Factors affecting cognitive functioning in a sample of human immunodeficiency virus-positive injection drug users. AIDS Patient Care STDs 2002; 16: 255-67.
49. McArthur JC, McClernon DR, Cronin MF, et al. Relationship between human immunodeficiency virus-associated dementia and viral load in cerebrospinal fluid and brain. Ann Neurol 1997; 42: 689-98.
50. Rothlind JC, Greenfield TM, Bruce AV, et al. Heavy alcohol consumption in individuals with HIV infection: effects on neuropsychological performance. J Inter Neuropsychol Soc 2005; 11: 70-83.
51. Bornstein RA, Nasrallah HA, Para MF, et al. Duration of illness and neuropsychological performance in asymptomatic HIV infection. J Neuropsychiatry Clin Neurosci 1994; 6: 160-4.
52. Basso MR, Bornstein RA. Effects of immunosuppression and disease severity upon neuropsychological function in HIV infection. J Clin Exp Neuropsychol 2000; 22: 104-14.
53. Letendre SL, McCutchan JA, Childers ME, et al. Enhancing antiretroviral therapy for human immunodeficiency virus cognitive disorders. Ann Neurol 2004; 56: 416-23.
54. Cherner M, Letendre S, Heaton RK, et al. Hepatitis C augments cognitive deficits associated with HIV infection and methamphetamine. Neurology 2005; 64: 1343-7.
55. Clifford DB, Yang Y, Evans S. Neurologic consequences of hepatitis C and human immunodeficiency virus coinfection. J Neurovirol 2005; 11: 67-71.
56. Morgello S, Estanislao L, Ryan E, et al. Effects of hepatic function and hepatitis C virus on the nervous system assessment of advanced-stage HIV-infected individuals. AIDS 2005; 19: 116-22.
57. Parsons TD, Tucker KA, Hall CD, et al. Neurocognitive functioning and HAART in HIV and hepatitis C virus co-infection. AIDS 2006; 20: 1591-5.
58. Castellon SA, Hardy DJ, Hinkin CH, et al. Components of depression in HIV-1 infection: Their differential relationship to neurocognitive performance. J Clin Exp Neuropsychol 2006; 28: 420-37.
59. Becker JT, Lopez OL, Dew MA, et al. Prevalence of cognitive disorders differs as a function of age in HIV virus infection. AIDS 2004; 18: 11-8.
60. Cherner M, Ellis RJ, Lazzaretto D, et al. Effects of HIV-1 infection and aging on neurobehavioral functioning: preliminary findings. AIDS 2004; 18: 27-34.
61. Rosenberger PH, Bornstein RA, Nasrallah HA, et al. Psychopathology in human immunodeficiency virus infection: lifetime and current assessment. Compr Psychiatry (1993); 34: 150-8.
62. Hartman D E. Neuropsychological toxicology (2nd ed.). New York: Plenum, 1995.
63. Bolla KI, Cadet JL, London ED. The neuropsychiatry of chronic cocaine abuse. J Neuropsychiatry Clin Neurosci 1998; 10: 280-9.
64. Pearlson GD, Jeffery PJ, Harris GJ, et al. Correlation of acute cocaine-induced changes in local cerebral blood flow with subjective effects. Am J Psychiatry 1993; 150: 495-7.
65. Kosten TR, Cheeves C, Palumbo J, et al. Regional cerebral blood flow during acute and chronic abstinence from combined cocainealcohol abuse. Drug Alcohol Depend 1998; 50: 187-95.
66. Pascual-Leone A, Dhuna A, Anderson DC. Cerebral atrophy in habitual cocaine abusers: A planimetric CT study. Neurology 1991a; 41: 34-38.
67. Strickland TL, Mena I, Villanueva-Meyer J, et al. Cerebral perfusion and neuropsychological consequences of chronic cocaine use. J Neuropsychiatry Clin Neurosci 1993; 5: 419-27.
68. Volkow ND, Mullani N, Gould KL, et al. Cerebral blood flow in chronic cocaine users: A study with positron emission tomography. Br J Psychiatry 1988; 152: 641-8.
69. Pascual-Leone A, Dhuna A, Anderson DC. Long-term neurological complications of chronic, habitual cocaine abuse. Neurotoxicology 1991b; 12: 393-400.
70. Hoff AL, Riordan H, Morris L, et al. Effects of crack cocaine on neurocognitive function. Psychiatry Res 1996; 60: 167-76.
71. Meek PS, Clark HW, Solana VL. Neurocognitive impairment: the unrecognized component of dual diagnosis in substance abuse treatment. J Psychoactive Drugs 1989; 21: 153-60.
72. Berry J, Van Gorp WG, Herzberg DS, et al. Neuropsychological deficits in abstinent cocaine abusers: preliminary findings after two weeks of abstinence. Drug Alcohol Depend 1993; 32: 231-7.
73. Van Gorp WG, Wilkins JN, Hinkin CH, et al. Declarative and procedural memory functioning in abstinent cocaine abusers. Arch Gen Psychiatry 1999; 56: 85-9.
74. Di Sclafani V, Clark HW, Tolou-Shams M, et al. Premorbid brain size is a determinant of functional reserve in abstinent crackcocaine and crack-cocaine-alcohol-dependent adults. J Int Neuropsychol Soc 1998; 4 (6): 559-65.
75. Ardila A, Rosselli M, Strumwasser S. Neuropsychological deficits in chronic cocaine abusers. Int J Neurosci 1991; 57: 73-9.
76. Baldwin GC, Roth MD, Tashkin DP. Acute and chronic effects of cocaine on the immune system and the possible link to AIDS. J Neuroimmunol 1998; 83: 133-8.
77. Karlix JL, Behnke M, Davis-Eyler F, et al. Cocaine suppresses fetal immune system. Pediatr Res 1998; 44: 43-6.
78. Delafuente JC, DeVane CL. Immunologic effects of cocaine and related alkaloids. Immunopharmacol Immunotoxicol 1991; 13: 11-23.
79. Peterson PK, Gekker G, Chao CC, et al. Cocaine potentiates HIV-1 replication in human peripheral blood mononuclear cell cocultures. Involvement of transforming growth factor-beta. J Immunology 1991; 146: 81-4.
80. Nottet HS, Persidsky Y, Sasseville VG, et al. Mechanisms for the transendothelial migration of HIV-1-infected monocytes into brain. J Immunology 1996; 156: 1284-95.
81. Zhang L, Looney D, Taub D, et al. Cocaine opens the blood-brain barrier to HIV-1 invasion. J Neurovirology 1998; 4: 619-26.
82. Durvalsala RS, Myers HF, Satz P, et al. HIV-1, cocaine, and neuropsychological performance in African American men. J Int Neuropsychol Soc 2000; 6(3): 322-35.
83. Levine AJ, Hardy DJ, Miller E, et al. The effect of recent stimulant use on sustained attention in HIV-infected adults. J Clin Exp Neuropsychol 2006; 28 (1): 29-42.
84. Pezawas LM, Fischer G, Diamant K, et al. Cerebral CT findings in male opioid-dependent patients: stereological, planimetric and linear measurements. Psychiatry Res 1998; 83: 139-47.
85. Strang J, Gurling H. Computerized tomography and neuropsychological assessment in long-term high-dose heroin addicts. Br J Addict 1989; 84: 1011-9.
86. Rose JS, Branchey M, Buydens-Branchey L, et al. Cerebral perfusion in early and late opiate withdrawal: a technetium-99m-HMPAO SPECT study. Psychiatry Res 1996; 67: 39-47.
87. Danos P, Kasper S, Grunwald F, et al. Pathological regional cerebral blood flow in opiate-dependent patients during withdrawal: a HMPAO-SPECT study. Neuropsychobiology 1998; 37: 194-9.
88. Fields FRJ, Fullerton JR. Influence of heroin addiction on neuro-psychological functioning. J Consult Clin Psychol 1975; 43: 114.
89. Sjogren P, Christrup LL, Petersen MA, et al. Neuropsychological assessment of chronic non-malignant pain patients treated in multidisciplinary pain centre. Eur J Pain 2005; 9(4): 453-62.
90. Davis PE, Liddiard H, McMillan TM. Neuropsychological deficits and opiate abuse. Drug Alcohol Depend 2002; 67(1): 105-8.
91. Sjogren P, Thomsen AB, Olsen AK. Impaired neuropsychological performance in chronic nonmalignant pain patients receiving longterm oral opioid therapy. J. Pain Symptom Manage. 2000; 19(2): 100-8.
92. O'Neill WM, Hanks GW, Simpson P, et al. The cognitive and psychomotor effects of morphine in healthy subjects: a randomized controlled trail of repeated (four) oral doses of dextropropoxyphene, morphine, lorazepam and placebo. Pain 2000; 85(1-2): 209-15.
93. Amir T, Bahri T. Effect of substance use on visuographic function. Percept Mot Skills 1994; 78(1): 235-41.
94. Vazquez-Justo E, Rodriguez Alvarez M, Carro Ramos J. Neuropsychological performance in HIV/AIDS intravenous drug users. J Clin Exp Neuropsychol 2003; 25: 852-65.
95. Verdejo-Garcia A, Toribio I, Orozco C, Puente KL, Perez-Garcia M. Neuropsychological functioning in methadone maintenance patients versus abstinent heroin abusers. Drug Alcohol Depend 2005; 78(3): 283-8.
96. Arora PK, Fride E, Petitto J, et al. Morphine-induced immune alterations in vivo. Cell Immunol 1990; 126: 343-53.
97. Rouveix B. Opiates and immune function. Consequences on infectious diseases with special reference to AIDS. Therapie 1992; 47: 503-12.
98. Govitrapong P, Suttitum T, Kotchabhakdi N, et al. Alterations of immune functions in heroin addicts and heroin withdrawal subjects. J Pharmacol Exp Ther 1998; 286: 883-9.
99. Schweitzer C, Keller F, Schmitt MP, et al. Morphine stimulates HIV replication in primary cultures of human Kupffer cells. Res Virology 1991; 142: 189-95.
100. Di Franco MJ, Marlink R, Hunter DJ, et al. Association of immune activation with intravenous heroin use and methadone treatment in HIV-1 seropositive and seronegative subjects. J Acquire Immune Defic Syndr 1993; 6: 1297-300.
101. Lucas GM, Gebo KA, Chaisson RE, et al. Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic. AIDS 2002; 16: 767-74.
102. Basso MR, Bornstein RA. Effects of immunosuppression and disease severity upon neuropsychological function in HIV infection. J Clin Exp Neuropsychol 2000; 22: 104-14.
103. Margolin A, Avants SK, Warburton LA, et al. Factors affecting cognitive functioning in a sample of human immunodeficiency virus-positive injection drug users. AIDS Patient Care STDs 2002; 16: 255-67.
104. Rothlind JC, Greenfield TM, Bruce AV. Heavy alcohol consumption in individuals with HIV infections: effects of neuropsychological performance. J Int Neuropsychol Soc 2005; 11: 70-83.
105. McArthur JC, Selnes OA, Glass JD, et al. HIV dementia. Incidence and risk factors. Res Publ Assoc Res Nerv Ment Dis 1994; 74: 251-72.
106. Concha M, Selnes OA, Vlahov D, et al. Comparison of neuropsychological performance between AIDS-free injecting drug users and homosexual men. Neuroepidemiology 1997; 16: 78-85.
107. Del Pesce M, Franciolini B, Censori B, et al. Cognitive behavior in asymptomatic (CDC stage II and III) HIV--seropositive intravenous drug users (IVDUs). Ital J Neurol Sci 1993; 14: 619-25.
108. Kovner R, Lazar JW, Lesser M, et al. Use of the dementia rating scale as a test for neuropsychological dysfunction in HIV-positive IV drug abusers. J Subst Abuse Treat 1992; 9: 133-7.
109. Wellman MC. Neuropsychological impairment among intravenous drug users in pre-AIDS stages of HIV infection. Int J Neurosci 1992; 64: 183-94.
110. Vazquez-Justo E, Rodriguez Alvarez M, Carro Ramos J. Neuropsychological performance in HIV/AIDS intravenous drug users. J Clin Exp Neuropsychol 2003; 25: 852-65.
111. Rodriguez SD, Rodriguez AM, Seoane Pesqueira G. Neuropsychological impairment among asymptomatic HIV-positive former intravenous drug users. Cogn Behav Neurol 2006; 19: 95-104.
112. Petry NM. Alcohol use in HIV patients: what we don't know may hurt us. Int J STDs AIDS 1999; 10: 561-70.
113. Wilkinson DA. Discussion: CT scan and neuropsychological assessments of alcoholism. In: Parsons OA, Butters N, Nathan PE, Eds. Neuropsychology of alcoholism: Implications for diagnosis and treatment (pp. 76-102). New York: Guilford Press; 1987.
114. Jernigan TL, Butters N, DiTraglia G, et al. Reduced cerebral grey matter observed in alcoholics using magnetic resonance imaging. Alcohol Clin Exp Res 1991; 15: 418-27.
115. Gilman S, Adams K, Koeppe RA, et al. Cerebellar and frontal hypometabolism in alcoholic cerebellar degeneration studied with positron emission tomography. Ann Neurol 1990; 28(6): P775-85.
116. Adams KM, Gilman S, Koeppe RA, et al. Neuropsychological deficits are correlated with frontal hypometabolism in positron emission tomography studies of older alcoholic patients. Alcohol Clin Exp Res 1993; 17: 205-10.
117. Berglund M, Hagstadius S, Risberg J, et al. Normalization of regional cerebral blood flow in alcoholics during the first 7 weeks of abstinence. Acta Psychiatr Scand 1987; 75: 202-8.
118. Parsons OA, Leber WR. The relationship between cognitive dysfunction and brain damage in alcoholics: Causal, interactive or epiphenomenal? Alcohol Clin Exp Res 1981; 5: 326-43.
119. Kramer JH, Blusewicz MJ, Preson KA. The premature aging hypothesis: Old before its time? J Consult Clin Psychol 1989; 57: 257-62.
120. Glenn SW, Parsons OA. Neuropsychological efficiency measures in male and female alcoholics. J Stud Alcohol 1992; 53: 546-52.
121. Parsons OA, Nixon SJ. Neurobehavioral sequelae of alcoholism. Neurologic Clinics 1993; 11: 205-18.
122. Beatty WW, Katzung VM, Moreland VJ, et al. Neuropsychological performance of recently abstinent alcoholics and cocaine abusers. Drug Alcohol Depend 1995; 37: 247-53.
123. Brandt J, Butters N, Ryan C, et al. Cognitive loss and recovery in long-term alcohol abusers. Arch Gen Psychiatry 1983; 40: 435-42.
124. Cook RT. Alcohol abuse, alcoholism, and damage to the immune system--a review. Alcohol Clin Exp Res 1998; 22: 1927-42.
125. Kronfol Z, Nair M, Hill E, et al. Immune function in alcoholism: a controlled study. Alcohol Clin Exper Res 1993; 17: 279-83.
126. Jerrells TR, Slukvin I, Sibley D, et al. Increased susceptibility of experimental animals to infectious organisms as a consequence of ethanol consumption. Alcohol Alcohol Suppl 1994; 2: 425-30.
127. Szabo, G. Consequences of alcohol consumption on host defense. Alcohol Alcohol 1999; 34: 830-41.
128. Tonnesen H, Kaiser AH, Nielsen BB, et al. Reversibility of alcohol-induced immune depression. Br J Addict 1992; 87: 1025-8.
129. Watson RR, Borgs P, Witte M, et al. Alcohol, immunomodulation, and disease. Alcohol Alcohol 1994; 29: 131-9.
130. Thiele GM, Szabo G, Kovacs EJ, et al. Modulation of immunity and viral-host interactions by alcohol. Alcohol Clin Exp Res 2002; 26: 1897-908.
131. Spies CD, von Dossow V, Eggers V, et al. Altered cell-mediated immunity and increased postoperative infection rate in long-term alcoholic patients. Anesthesiology 2004; 100: 1088-00.
132. Bagasra O, Kajdacsy-Balla A, Lischner HW, et al. Alcohol intake increases human immunodeficiency virus type 1 replication in human peripheral blood mononuclear cells. J Infect Dis 1993; 167: 789-97.
133. Wang JY, Liang B, Watson RR. Alcohol consumption alters cytokine release during murine AIDS. Alcohol 1997; 14: 155-9.
134. Witte MH, Borgs P, Way DL, et al. AIDS, alcohol, endothelium, and immunity. Alcohol 1994; 11: 91-7.
135. McArthur JC, Kumar AJ, Johnson DW, et al. Incidental white matter hyperintensities on magnetic resonance imaging in HIV-1 infection. Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr 1990; 3(3): 252-9.
136. Meyerhoff DJ, MacKay S, Sappey-Marinier D, et al. Effects of chronic alcohol abuse and HIV infection on brain phosphorus metabolites. Alcohol Clin Exp Res 1995; 19(3): 685-92.
137. Bornstein RA, Fama R, Rosenberger P, et al. Drug and alcohol use and neuropsychological performance in asymptomatic HIV infection. J Neuropsychiatry 1993; 5(3): 254-9.
138. Green JE, Saveanu RV, Bornstein RA. The effect of previous alcohol abuse on cognitive function in HIV Infection. Am J Psychiatry 2004; 61: 249-54.
139. Sassoon SA, Fama R, Rosenbloom MJ, et al. Component cognitive and motor processes of the digit symbol tests: differential deficits in alcoholism, HIV infection, and their comorbidity. Alcohol Clin Exp Res 2007; 31(8): 1-10.
140. Durvasula RS, Myers HF, Mason K, Hinkin CH. Relationship between alcohol use/abuse, HIV infection and neuropsychological performance in African American men. J Clin Exp Neuropsychol 2006; 28: 383-404.
141. Dingle GA, Oie TP. Is alcohol a cofactor of HIV and AIDS?: evidence from immunological and behavioral studies. Psychol Bull 1997; 122: 56-71.
142. Hampson RE, Deadwyler SA. Role of cannabinoid receptors in memory storage. Neurobiological Disease 1998; 5: 474-82.
143. Jentsch JD, Dazzi L, Chhatwal JP, et al. Reduced prefrontal cortical dopamine, but not acetylcholine, release in vivo after repeated, intermittent phencyclidine administration to rats. Neurosci Lett 1998; 258: 175-8.
144. Amen DG, Waugh M. High resolution brain SPECT imaging of marijuana smokers with AD/HD. J Psychoactive Drugs 1998; 30: 209-14.
145. Tunving K, Thulin SO, Risberg J, et al. Regional cerebral blood flow in long-term heavy cannabis use. Psychiatry Res 1986; 17: 15-21.
146. Leirer VO, Yesavage JA, Morrow DG. Marijuana, aging, and task difficulty effects on pilot performance. Aviat Space Env Med 1989; 60: 1145-52.
147. Pope HG Jr, Gruber AJ, Yurgelun-Todd DA. The residual neuropsychological effects of cannabis: the current status of research. Drug Alcohol Depend 1995; 8: 25-34.
148. Pope HG Jr, Jacobs A, Mialet JP, et al. Evidence for a sex-specific residual effect of cannabis on visuospatial memory. Psychother Psychosom 1997; 66: 179-84.
149. Pope HG Jr, Yurgelun-Todd D. The residual cognitive effects of heavy marijuana use in college students. JAMA 1996; 275: 521-7.
150. Klein TW, Friedman H, Specter S. Marijuana, immunity and infection. J Neuroimmunol 1998; 83: 102-15.
151. Klein TW, Newton C, Friedman H. Inhibition of natural killer cell function by marijuana components. J Toxicol Environ Health 1987; 20: 321-32.
152. Pillai R, Nair BS, Watson RR. AIDS, drugs of abuse and the immune system: a complex immunotoxicological network. Arch Toxicol 1991; 65: 609-17.
153. Srivastava MD, Srivastava BI, Brouhard B. Delta9 tetrahydrocannabinol and cannabidiol alter cytokine production by human immune cells. Immunopharmacology 1998; 40: 179-85.
154. Cristiani SA, Pukay-Martin ND, Bornstein RA. Marijuana use and cognitive function in HIV-infected people. J Neuropsychiatry Clin Neurosci 2004; 16: 330-5.
155. Feldman RS, Quenzer LF. Fundamentals of neuropsychopharmacology. Sunderland, MA: Sinauer Associates, 1984.
156. McCann UD, Wong DF, Yokoi F, et al. Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: evidence from positron emission tomography studies with [11C]WIN-35,428. J Neurosci 1998; 18: 8417-22.
157. Ernst M, Zametkin AJ, Matochik J, et al. Intravenous dextroamphetamine and brain glucose metabolism. Neuropsychopharmacology 1997; 17: 391-401.
158. Kahn DA, Prohovnik I, Lucas LR, et al. Dissociated effects of amphetamine on arousal and cortical blood flow in humans. Biol Psychiatry 1989; 25: 755-67.
159. Kao CH, Wang SJ, Yeh SH. Presentation of regional cerebral blood flow in amphetamine abusers by 99Tcm-HMPAO brain SPECT. Nucl Med Comm 1994; 15: 94-98.
160. Iyo M, Namba H, Yanagisawa M, et al. Prog. Neuropsychopharmacol. Biol Psychiatry 1997; 21: 789-96.
161. Vollenweuder FX, Maquire RP, Leenders KL, et al. Effects of high amphetanube dose on mood and cerebral glucose metabolism in normal volunteers using positron emission tomography (PET). Psychiatry Res 1998; 83(3): 149-62.
162. McKetin R, Mattick RP. Attention and memory in illicit amphetamine users. Drug Alcohol Depend 1997; 48: 235-242-44.
163. McKetin R, Mattick RP. Attention and memory in illicit amphetamine users: comparison with non-drug-using controls. Drug Alcohol Depend 1998; 50: 181-4.
164. Nunez M J, Fernandez-Rial JC, Couceiro J, et al. Effects of amphetamine on influenza virus infection in mice. Life Sci 1993; 52: 73-8.
165. Nunez-Iglesias MJ, Castro-Bolano C, Losada C, et al. Effects of amphetamine on cell mediated immune response in mice. Life Sci 1996; 58: 29-33.
166. Basso AM, Gioino G, Molina VA, et al. Chronic amphetamine facilitates immunosuppression in response to a novel aversive stimulus: reversal by haloperidol pretreatment. Pharmacol Biochem Behav 1999; 62: 307-14.
167. Freire-Garabal M, Balboa JL, Nunez MJ, et al. Effects of amphetamine on T-cell immune response in mice. Life Sci 1991; 49: 107-12.
168. Swerdlow NR, Hauger R, Irwin M, et al. Endocrine, immune, and neurochemical changes in rats during withdrawal from chronic amphetamine intoxication. Neuropsychopharmacology 1991; 5: 23-31.
169. Jernigan TL, Gamst AC, Archibald SL, et al. Effects of methamphetamine dependence and HIV infection on cerebral morphology. Am J Psychiatry 2005; 162(8): 1461-72.
170. Taylor MJ, Schweinsburg BC, Alhassoon OM, et al. Concordance of MR spectroscopic and neuropsychological deficits in HIV and methamphetamine dependence. J Int Neuropsychol Soc 2002; 8 (2): 314.
171. Khalsa JH, Royal W. Do drugs of abuse impact on HIV disease? J Neuroimmunol 2004; 147(1-2): 6-8.
172. Carey CL, Woods SP, Rippeth JD, et al. Additive deleterious effects of methamphetamine dependence and immunosuppression on neuropsychological functioning in HIV infection. AIDS Behav 2006; 10(2): 185-90.
173. Flora G, Lee YW, Nath A, et al. Methamphetamine potentiates HIV-1 Tat protein-mediated activation of redox-sensitive pathways in discrete regions of the brain. Exp. Neurol 2003; 179(1): 60-70.
174. Nath A, Hauser KF, Wojna V, et al. Molecular basis for interactions of HIV and drugs of abuse. J Acquir Immune Defic Syndr 2002; 31(Suppl 2): S62-9.
175. Nordahl TE, Salo R, Leamon M. Neuropsychological effects of chronic methamphetamine use on neurotransmitters and cognition: a review. J. Neuropsychiatry Clin Neurosci 2003; 15(3): 317-25.
176. Rippeth JD, Heaton RK, Carey CL, et al. Methamphetamine dependence increase risk of neuropsychological impairment in HIV infected persons. J Int Neuropsychol Soc 2004; 10: 1-14.
177. Levine AJ, Hardy DJ, Barclay TR, et al. Elements of attentions in HIV-infected adults: evaluation of an existing model. J Clin Exp Neuropsychol 2007; 1: 1-10.
178. Jarvik JG, Lenkinski RE, Saykin AJ, et al. Proton spectroscopy in asymptomatic HIV-infected adults: initial results in a prospect cohort study. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 13 (3): 247-53.
179. Failde Garrido JM, Lopez Castro J, Fernandez Rodriquez V, et al. HIV-infection, use of drugs and neuropsychologic efficiency. An Med Interna 2005; 22 (12): 569-74.
180. Grassi MP, Clerici F, Perin C, et al. HIV infection and drug use: influence on cognitive function. AIDS 1995; 9(2): 165-70.
181. Mason KI, Campbell A, Hawkins P, et al. Neuropsychological functioning in HIV-positive African American women with a history of drug use. J Nat Med Assoc 1998; 90(11): 665-74.
182. Heaton RK, Ryan L, Grant I, et al. Demographic influences on neuropsychological test performance. In: Grant I, Adams KM, Eds. Neuropsychological assessment of neuropsychiatric disorders, 2nd Edition. New York: Oxford University Press 1996; pp. 141-163.
183. Hinkin CH, Hardy DJ, Mason KI, et al. Medication adherence in HIV-infected adults: effect of patient age, cognitive status, and substance abuse. AIDS 2004; 18(Suppl 1): S19-S25.
184. Nelson GW, O'Brien SJ. Using mutual information to measure the impact of multiple genetic factors on AIDS. J Acquir Immune Defic Syndr 2006; 42(3): 347-54.
185. Copenhaver M, Avants SK, Warburton LA, et al. Intervening effectively with drug abusers infected with HIV: taking into account the potential for cognitive impairment. J. Psychoactive Drugs 2003; 35(2): 209-18.
186. Avants SK. Holistic health recovery program for HIV+ drug users: a treatment manual for addiction counselors. New Haven, CT: Yale University School of Medicine 2001.